Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entacingene turiparvovec
- Development stage
- Phase 2
- Lead developer
- MeiraGTx Holdings
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intraocular, Subretinal, Ophthalmic
01
Overview
Entacingene turiparvovec is an investigational adeno-associated virus (AAV) based gene therapy designed to treat inherited color vision defects, specifically achromatopsia caused by mutations in the CNGB3 gene. The therapy uses an AAV serotype 8 vector to deliver a functional copy of the human CNGB3 gene directly to retinal cells via intraocular injection, aiming to restore or improve cone photoreceptor function and color vision. It is being developed by MeiraGTx in collaboration with Johnson & Johnson Innovative Medicine (formerly Janssen Pharmaceuticals), with originator rights from UCL Business. Entacingene turiparvovec has received orphan drug designation for color vision defects and is currently in Phase I/II clinical trials for achromatopsia[1][2][3][6].
- Other names
- Adenovirus associated viral vector serotype 8 containing the human CNGB3 gene
02
Targets
CNGB3 (Cyclic nucleotide-gated channel beta 3)
Beyond the preview
Go deeper on entacingene turiparvovec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entacingene turiparvovec.